DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/9px9n8/acute_ischemic) has announced the addition of the "Acute Ischemic Stroke - Pipeline Review, H2 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Acute Ischemic Stroke, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Ischemic Stroke and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AB Science SA
- AstraZeneca Plc
- Biogen, Inc.
- D-Pharm Ltd.
- Daiichi Sankyo Company, Limited
- DiaMedica Inc.
- Digna Biotech, S.L.
- Glucox Biotech AB
- Grifols, S.A.
- Lumosa Therapeutics Co., Ltd.
- Mitsubishi Tanabe Pharma Corporation
- Pharmicell Co., Ltd.
- PhytoHealth Corporation
- Remedy Pharmaceuticals, Inc.
- Simcere Pharmaceutical Group
- Stemedica Cell Technologies, Inc.
- ZZ Biotech, LLC
Drug Profiles
- 3K3A-APC
- Cerecellgram-Stroke
- DB-017
- DM-199
- DS-1040
- glyburide
- HBN-1
- Human Plasmin
- LT-3001
- masitinib
- Mesenchymal Stem Cells
- MP-124
- natalizumab
- Peptide to Agonize GHSR-1a for Sepsis, Acute Radiation Syndrome and Acute Ischemic Stroke
- PHN-014
- Recombinant Plasmin
- SIM-071201
- Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke
- Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke
- THR-18
- ticagrelor
- TS-01
For more information visit http://www.researchandmarkets.com/research/9px9n8/acute_ischemic
